1.
Blauvelt A, Rich P, Sofen H, Lambert J, Merola JF, Lebwohl M, Scharnitz T, Hoyt K, Kisa RM, Banerjee S. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in scalp, nail, and palmoplantar psoriasis: subgroup analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. J of Skin [Internet]. 2022Nov.16 [cited 2024Jul.19];6(6):s49. Available from: https://jofskin.org/index.php/skin/article/view/1804